Mirabegron Eg

Mirabegron, the active ingredient in Mirabegron Eg, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is a β3‑adrenergic receptor agonist used in the management of overactive bladder.

- Overactive bladder: improves bladder capacity and reduces urgency episodes. - Urinary urgency: decreases the frequency of sudden urges to void. - Urge urinary incontinence: lowers the number of involuntary leakage episodes.

Adverse reactions may occur with Mirabegron use.

Common Side Effects: - Hypertension: elevated blood pressure readings. - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: intermittent mild to moderate pain. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder. - Severe hypertension: markedly high blood pressure requiring medical attention. - Tachycardia: rapid heart rate. - Angioedema: swelling of face, lips, or throat. - Allergic reactions: rash, itching, or anaphylaxis.

Before prescribing Mirabegron, clinicians should consider several safety measures.

- Assess cardiovascular status: monitor blood pressure regularly. - Evaluate renal function: adjust use in patients with impaired kidneys. - Review concomitant medications: avoid strong CYP2D6 inhibitors. - Use caution in uncontrolled hypertension: consider alternative therapy. - Monitor for urinary retention: advise patients to report difficulty voiding. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirabegron may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase Mirabegron exposure. - Co‑administration with other β3‑adrenergic agonists: risk of additive cardiovascular effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may modestly raise plasma levels. - Diuretics: combined effect on blood pressure should be observed. - NSAIDs: may enhance risk of hypertension.